Drugmakers, including Gilead Sciences Inc, Bristol-Myers Squibb Co, and Biogen Inc have hiked their U.S. list prices on more than 50 drugs, according to data analyzed by 3 Axis Advisors, a healthcare research firm. On Tuesday, there were media reports… Read More ›
The strategic move will enable Roche Holding AG to add Foundation Medicine’s portfolio of drugs to its basket of cancer treatments. FMI’s molecular insights will also enable Roche to create and develop new cancer treatments. On Tuesday, Swiss drugmaker Roche… Read More ›
manageria.biz 